Wednesday, June 25, 2025 | 01:50 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid-19: CSIR gets nod for phase III trials of antiviral drug Umifenovir

Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients

hospital, beds, patients, doctors, nurses, health care, health workers, coronavirus, testing, vaccine
premium

This drug has a good safety profile and acts by preventing entry of virus into human cells and also by priming the immune system, Ministry of Science and Technology said I'm a statement.

IANS

Amid the race to find a cure for the deadly coronavirus infection, Council of Scientific and Industrial Research (CSIR)-constituent lab CSIR-Central Drug Research Institute (CDRI) in Lucknow has received permission to carry out Phase III trial of antiviral drug Umifenovir.

Umifenovir is mainly used for treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid19 patients.

Announcing the commencement of trial, Union Health Minister Harsh Vardhan said: "CSIR's constituent lab CSIR-Central Drug Research Institute (CDRI) Lucknow, has received permission for carrying out Phase III randomised, Double-blind, Placebo-controlled trial of